Close Menu

NEW YORK (GenomeWeb) – Promega said today that it has non-exclusively licensed the Broad Institute's CRISPR-Cas9 intellectual property.

Under the terms of the agreement, Promega will combine the Broad's CRISPR-Cas9 technology with its own products for knock-in of genetic reporters into the genomes of any cell or cell line. The firm is aiming to develop and sell gene editing tools and reagents for interrogating endogenous biology at physiologically relevant expression levels.

Financial terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.